| Help | About | Contact Us

Publication : High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.

First Author	Gao H	Year	2015
Journal	Nat Med	Volume	21
Issue	11	Pages	1318-25
PubMed ID	26479923	Mgi Jnum	J:227402
Mgi Id	MGI:5700429	Doi	10.1038/nm.3954
Citation	Gao H, et al. (2015) High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med 21(11):1318-25

abstractText

Profiling candidate therapeutics with limited cancer models during preclinical development hinders predictions of clinical efficacy and identifying factors that underlie heterogeneous patient responses for patient-selection strategies. We established approximately 1,000 patient-derived tumor xenograft models (PDXs) with a diverse set of driver mutations. With these PDXs, we performed in vivo compound screens using a 1 x 1 x 1 experimental design (PDX clinical trial or PCT) to assess the population responses to 62 treatments across six indications. We demonstrate both the reproducibility and the clinical translatability of this approach by identifying associations between a genotype and drug response, and established mechanisms of resistance. In addition, our results suggest that PCTs may represent a more accurate approach than cell line models for assessing the clinical potential of some therapeutic modalities. We therefore propose that this experimental paradigm could potentially improve preclinical evaluation of treatment modalities and enhance our ability to predict clinical trial responses.

Your name:
Your email address:
Subject:
Message:	---- Current page: ---- /mousemine/report.do;jsessionid=838275E4A90FFE3A817C57593A5CEA59?id=83600511&trail=%7C83600511

MouseMine

Publication : High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.

External Links

Expression

Publication --> Expression annotations

Other

64 Authors

0 Bio Entities

0 Expression